Risks factors for infections with extended-spectrum beta-lactamase- producing escherichia coli and klebsiella pneumoniae at a tertiary care university hospital in Switzerland

Infection

Volumn 38, Issue 1, 2010, Pages 33-40

  Kuster, S P ^a   Hasse, B ^a   Huebner, V ^a   Bansal, V ^a   Zbinden, R ^b   Ruef, C ^a   Ledergerber, B ^a   Weber, R ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; EXTENDED SPECTRUM BETA LACTAMASE; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; ARTIFICIAL VENTILATION; BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERIUM ISOLATE; BACTERIUM ISOLATION; BLOODSTREAM INFECTION; CATHETER INFECTION; CONTROLLED STUDY; ESCHERICHIA COLI; FEMALE; HOSPITAL PATIENT; HUMAN; INTENSIVE CARE UNIT; INTRAVASCULAR CATHETER; KLEBSIELLA PNEUMONIAE; MAJOR CLINICAL STUDY; MALE; NONHUMAN; OUTPATIENT; PREVALENCE; RISK FACTOR; SWITZERLAND; SYMPTOM; TERTIARY HEALTH CARE; UNIVERSITY HOSPITAL; URINARY TRACT INFECTION;

ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; CASE-CONTROL STUDIES; COMMUNITY-ACQUIRED INFECTIONS; CROSS INFECTION; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; HOSPITALS, UNIVERSITY; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; RISK FACTORS; SWITZERLAND; TRAVEL;

EID: 77549084308     PISSN: 03008126     EISSN: None     Source Type: Journal    
DOI: 10.1007/s15010-009-9207-z     Document Type: Article

References (27)

1. M. Tumbarello T. Spanu M. Sanguinetti R. Citton E. Montuori F. Leone G. Fadda R. Cauda 2006 Bloodstream infections caused by extended-spectrum-beta- lactamase-producing Klebsiella pneumoniae: risk factors, molecular epidemiology, and clinical outcome Antimicrob Agents Chemother 50 498 504 10.1128/AAC.50.2.498-504.2006 1:CAS:528:DC%2BD28XhsFegt7s%3D 16436702 (Pubitemid 43190958)
2. C. Pena C. Gudiol F. Tubau M. Saballs M. Pujol M.A. Dominguez L. Calatayud J. Ariza F. Gudiol 2006 Risk-factors for acquisition of extended-spectrum beta-lactamase-producing Escherichia coli among hospitalised patients Clin Microbiol Infect 12 279 284 10.1111/j.1469-0691.2005.01358.x 1:CAS:528:DC%2BD28XjsFOrtbk%3D 16451416 (Pubitemid 43379330)
3. L.R. Peterson 2008 Antibiotic policy and prescribing strategies for therapy of extended-spectrum beta-lactamase-producing Enterobacteriaceae: the role of piperacillin-tazobactam Clin Microbiol Infect 14 181 184 10.1111/j.1469-0691.2007.01864.x 1:CAS:528:DC%2BD1cXhtlehsr4%3D 18154544 (Pubitemid 350269200)
4. D.L. Paterson R.A. Bonomo 2005 Extended-spectrum beta-lactamases: a clinical update Clin Microbiol Rev 18 657 686 10.1128/CMR.18.4.657-686.2005 1:CAS:528:DC%2BD2MXht1Wrsr%2FE 16223952 (Pubitemid 41504510)
5. R.J. Cordery C.H. Roberts S.J. Cooper G. Bellinghan N. Shetty 2008 Evaluation of risk factors for the acquisition of bloodstream infections with extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species in the intensive care unit; antibiotic management and clinical outcome J Hosp Infect 68 108 115 10.1016/j.jhin.2007.10.011 1:STN:280: DC%2BD1c7ltV2gug%3D%3D 18063198
6. J. Rodriguez-Bano M.D. Navarro L. Romero M.A. Muniain M. Cueto J. Galvez E.J. Perea A. Pascual 2008 Risk-factors for emerging bloodstream infections caused by extended-spectrum betalactamase-producing Escherichia coli Clin Microbiol Infect 14 180 183 1:STN:280:DC%2BD1c%2FhslOjsA%3D%3D 18005358
7. M. Tumbarello M. Sali E.M. Trecarichi F. Leone M. Rossi B. Fiori G. De Pascale T. D'Inzeo M. Sanguinetti G. Fadda R. Cauda T. Spanu 2008 Bloodstream infections caused by extended-spectrum-betalactamase-producing Escherichia coli: risk factors for inadequate initial antimicrobial therapy Antimicrob Agents Chemother 52 3244 3252 10.1128/AAC.00063-08 1:CAS:528:DC%2BD1cXhtF2gtrfJ 18591273
8. R. Ramphal P.G. Ambrose 2006 Extended-spectrum beta-lactamases and clinical outcomes: current data Clin Infect Dis 42 S164 S172 10.1086/500663 1:CAS:528:DC%2BD28XktFajur4%3D 16544267
9. M.J. Schwaber S. Navon-Venezia K.S. Kaye R. Ben-Ami D. Schwartz Y. Carmeli 2006 Clinical and economic impact of bacteremia with extended- spectrum-beta-lactamase-producing Enterobacteriaceae Antimicrob Agents Chemother 50 1257 1262 10.1128/AAC.50.4.1257-1262.2006 1:CAS:528:DC%2BD28XjvFOku7s%3D 16569837
10. A. Asensio A. Oliver P. Gonzalez-Diego F. Baquero J.C. Perez-Diaz P. Ros J. Cobo M. Palacios D. Lasheros R. Cantón 2000 Outbreak of a multiresistant Klebsiella pneumoniae strain in an intensive care unit: antibiotic use as risk factor for colonization and infection Clin Infect Dis 30 55 60 10.1086/313590 1:STN:280:DC%2BD3c%2Fos1GgtA%3D%3D 10619733 (Pubitemid 30067062)
11. E. Calbo V. Romani M. Xercavins L. Gomez C.G. Vidal S. Quintana J. Vila J. Garau 2006 Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum beta-lactamases J Antimicrob Chemother 57 780 783 10.1093/jac/dkl035 1:CAS:528:DC%2BD28Xis1Glur0%3D 16492721
12. J. Rodriguez-Bano J.C. Alcala J.M. Cisneros F. Grill A. Oliver J.P. Horcajada T. Tortola B. Mirelis G. Navarro M. Cuenca M. Esteve C. Peña A.C. Llanos R. Cantón A. Pascual 2008 Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli Arch Intern Med 168 1897 1902 10.1001/archinte.168.17.1897 1:CAS:528:DC%2BD1cXhtF2rur7F 18809817
13. M.L. Berg C.W. Crank A.H. Philbrick M.K. Hayden 2008 Efficacy of ertapenem for consolidation therapy of extended-spectrum betalactamase-producing Gram-negative infections: a case series report Ann Pharmacother 42 207 212 10.1345/aph.1K365 1:CAS:528:DC%2BD1cXivVyrurY%3D 18230703 (Pubitemid 351238568)
14. D. Gulmez N. Woodford M.F. Palepou S. Mushtaq G. Metan Y. Yakupogullari S. Kocagoz O. Uzun G. Hascelik D.M. Livermore 2008 Carbapenem-resistant Escherichia coli and Klebsiella pneumoniae isolates from Turkey with OXA-48-like carbapenemases and outer membrane protein loss Int J Antimicrob Agents 31 523 526 10.1016/j.ijantimicag.2008.01.017 18339523
15. M.F. Lartigue C. Zinsius A. Wenger J. Bille L. Poirel P. Nordmann 2007 Extended-spectrum beta-lactamases of the CTX-M type now in Switzerland Antimicrob Agents Chemother 51 2855 2860 10.1128/AAC.01614-06 1:CAS:528:DC%2BD2sXoslOjurs%3D 17470647 (Pubitemid 47206222)
16. R.C. Bone R.A. Balk F.B. Cerra R.P. Dellinger A.M. Fein W.A. Knaus 1992 Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine Chest 101 1644 1655 10.1378/chest.101.6.1644 1:STN:280:DyaK383ovFeiuw%3D%3D 1303622
17. P.J. Collignon R. Munro 1989 Laboratory diagnosis of intravascular catheter associated sepsis Eur J Clin Microbiol Infect Dis 8 807 814 10.1007/BF02185853 1:STN:280:DyaK3c%2Fns1ahsA%3D%3D 2512155
18. J.C. McGregor P.W. Kim E.N. Perencevich D.D. Bradham J.P. Furuno K.S. Kaye J.C. Fink P. Langenberg M.-C. Roghmann A.D. Harris 2005 Utility of the Chronic Disease Score and Charlson Comorbidity Index as comorbidity measures for use in epidemiologic studies of antibiotic-resistant organisms Am J Epidemiol 161 483 493 10.1093/aje/kwi068 15718484 (Pubitemid 40315619)
19. J.C. McGregor E.N. Perencevich J.P. Furuno P. Langenberg K. Flannery J. Zhu J.C. Fink D.D. Bradham A.D. Harris 2006 Comorbidity risk-adjustment measures were developed and validated for studies of antibiotic-resistant infections J Clin Epidemiol 59 1266 1273 10.1016/j.jclinepi.2006.01.016 17098569 (Pubitemid 44708614)
20. J.S. Garner W.R. Jarvis T.G. Emori T.C. Horan J.M. Hughes 1988 CDC definitions for nosocomial infections, 1988 Am J Infect Control 16 128 140 10.1016/0196-6553(88)90053-3 1:STN:280:DyaL1czgvVSnug%3D%3D 2841893 (Pubitemid 18157352)
21. N.D. Friedman K.S. Kaye J.E. Stout S.A. McGarry S.L. Trivette J.P. Briggs W. Lamm C. Clark J. MacFarquhar A.L. Walton L.B. Reller D.J. Sexton 2002 Health care-associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections Ann Intern Med 137 791 797 12435215
22. Clinical and Laboratory Standards Institute/CLSI 2009: Performance standards for antimicrobial susceptibility testing, 17th Informational supplement. Clinical and Laboratory Standards Institute, Wayne. 2007.
23. C.I. Kang H.S. Cheong D.R. Chung K.R. Peck J.H. Song M.D. Oh K.W. Choe 2008 Clinical features and outcome of community-onset bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli Eur J Clin Microbiol Infect Dis 27 85 88 10.1007/s10096-007-0401-6 17943331 (Pubitemid 350197875)
24. R. Daza J. Gutierrez G. Piedrola 2001 Antibiotic susceptibility of bacterial strains isolated from patients with community-acquired urinary tract infections Int J Antimicrob Agents 18 211 215 10.1016/S0924-8579(01)00389-2 1:CAS:528:DC%2BD3MXnslWlsb8%3D 11673032 (Pubitemid 32979192)
25. T.M. Coque F. Baquero R. Canton 2008 Increasing prevalence of ESBL-producing Enterobacteriaceae in Europe Euro Surveill 13 1 11
26. M. Ferech S. Coenen S. Malhotra-Kumar K. Dvorakova E. Hendrickx C. Suetens 2006 Goossens H; ESAC Project Group European Surveillance of Antimicrobial Consumption (ESAC): outpatient quinolone use in Europe J Antimicrob Chemother 58 423 427 10.1093/jac/dkl183 1:CAS:528: DC%2BD28Xotl2ls7o%3D 16735418 (Pubitemid 44294958)
27. M. Fillipini G. Masiero K. Moschetti 2006 Socioeconomic determinants of regional differences in outpatient antibiotic consumption evidence from Switherland Health Policy 78 77 92 10.1016/j.healthpol.2005.09.009 (Pubitemid 44108323)